NAPLES, Fla. And CAMBRIDGE, United Kingdom, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced the strategic acquisition of 8.65252366 Bitcoin (“BTC”) for an aggregate purchase price of $1,000,000 (inclusive of fees and expenses), at an average acquisition price of $115,285 per BTC. By incorporating Bitcoin into its treasury reserve strategy, CDT aims to strengthen its financial position and reinforce balance sheet resilience, while aligning with the ac ...

Core Viewpoint - CDT Equity Inc. has approved a cryptocurrency-based treasury reserve strategy to diversify its capital management approach and enhance its innovation-led model [1][2] Group 1: Treasury Reserve Strategy - The strategy aims to hold part of the current balance sheet in digital assets, reflecting the company's belief in the long-term strategic and financial benefits of exposure to cryptocurrencies [2] - The decision is influenced by significant market activity from investors in the cryptocurrency and stablecoin sector, positioning the company for potentially transformative transactions [2] Group 2: Technological Development - CDT is collaborating with Sarborg to create an autonomous AI-led system for evaluating the cryptocurrency market, which will provide real-time analytics and automated execution systems [3] - The company is also focused on advancing its pipeline of Phase-2 ready pharmaceutical assets, leveraging algorithmic repurposing and IP-led licensing opportunities [3] Group 3: Share Information - As of September 2, 2025, CDT has 3,382,025 shares of common stock outstanding, with a total of 250,000,000 authorized shares [4] - The company continues to utilize its at-the-market (ATM) facility with A.G.P./Alliance Global Partners as its primary funding source [4]

Using AI, CDT Equity Inc. identifies a novel therapeutic indication for its lead programmes, supported by successful pre-clinical trial dataNAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 26, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announces that it has successfully identified a new biological target and novel therapeutic indication for its lead programme, AZD1656 (and its derivatives), following positive data from pre-clinical studies. This affirms the Company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41245 CDT EQUITY INC. (Exact name of registrant as specified in its charter) | Delaware | 87-3272543 | | --- | --- | | (State or ...

Name change to CDT Equity Inc. reflects evolution of strategy and focus on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation, strategic partnerships and out- licensing NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the "Company") today announce that it intends to change its name to CDT Equity Inc. ("CDT") reflecting the evolution of its strategy as a data-driven biotech ...

Core Viewpoint - Conduit Pharmaceuticals Inc. is exploring the adoption of a partial cryptocurrency treasury reserve strategy to enhance capital diversification and align with digital asset trends [1][3]. Group 1: Strategic Initiative - The company has engaged a third-party consultant with expertise in the cryptocurrency sector to evaluate the potential benefits of this strategy [2][7]. - This initiative aims to inform the company about current cryptocurrency market dynamics and support a broader capital diversification framework [1][3]. Group 2: Technology and Innovation - Conduit continues to adopt a technology-led approach to enhance the development of its pharmaceutical assets, leveraging artificial intelligence and solid-form technologies [4]. - The company views the partial cryptocurrency reserve as a means to complement its innovation-led ethos and provide long-term optionality [3][4]. Group 3: Leadership Perspective - Dr. Andrew Regan, CEO of Conduit Pharmaceuticals, emphasized the ambition to innovate not only in science but also in capital structure and value creation [5]. - The company aims to position itself as a forward-thinking business at the intersection of pharmaceuticals, technology, and digital finance [4][5]. Group 4: Business Model - Conduit operates as a multi-asset clinical stage life science company, focusing on an efficient model for compound development and seeking exits through third-party license deals after successful clinical trials [5]. - The company’s approach is a departure from traditional pharma/biotech models, aiming to build an integrated platform-driven approach powered by AI and cybernetics [5].

Core Insights - Conduit Pharmaceuticals has filed four new patent applications for its key assets AZD1656 and AZD5658, marking the first patent filings for AZD5658, which significantly expands the company's intellectual property portfolio [1][6] - The new patents are based on combinations of Conduit's lead assets with existing therapies, identified through AI-led analysis in collaboration with Sarborg Limited, enhancing the company's ability to generate novel, data-driven intellectual property [2][6] - The Chief Scientific Officer of Conduit Pharmaceuticals emphasized that these filings validate the progress made through the partnership with Sarborg, uncovering therapeutic combinations with substantial commercial potential [3] Company Overview - Conduit Pharmaceuticals is a clinical-stage life science company that employs an efficient model for compound development, focusing on acquiring and funding Phase 2-ready assets [4] - The company utilizes a platform-driven approach powered by artificial intelligence and cybernetics, aiming for exits through third-party licensing deals after successful clinical trials [4] - The leadership team includes experienced executives such as Dr. Andrew Regan and Dr. Freda Lewis-Hall, indicating a strong foundation for the company's innovative approach [4]

Core Insights - Conduit Pharmaceuticals has entered a joint development agreement with Manoira Corporation to evaluate its glucokinase activators AZD1656 and AZD5658 for veterinary applications, particularly in animal osteoarthritis [1][2][3] - The collaboration aims to generate preclinical data that will inform Conduit's human clinical programs while retaining full ownership of all related intellectual property [3][5][6] - This partnership opens new revenue streams in the growing $15 billion animal health market, projected to grow at a CAGR of 6.5% through 2027 [7][6] Company Strategy - The agreement highlights Conduit's commitment to innovative collaborations that maximize resource efficiency and pipeline potential [4] - By leveraging Manoira's expertise, Conduit aims to accelerate the development of AZD1656 and explore cross-species value through targeted programs [5][6] - The partnership is designed to enhance Conduit's competitive edge in glucokinase activator therapies and create a dual-track value proposition for shareholders [3][7] Financial Aspects - Manoira will fund all development activities, while Conduit will issue an upfront consideration of $500,000 through the issuance of 154,799 shares of common stock [8] - The collaboration is expected to reduce development timelines and costs for human clinical trials, enhancing the probability of success for AZD1656 in human indications [7][6] - The joint development agreement allows Conduit to retain exclusive rights and ownership of all new intellectual property related to AZD1656 and AZD5658 for human applications [5][4]

Core Viewpoint - Conduit Pharmaceuticals Inc. has received approval from Nasdaq to transfer its common stock listing to The Nasdaq Capital Market, effective May 23, 2025, following compliance with necessary requirements [1]. Company Overview - Conduit Pharmaceuticals is a clinical stage life science company that employs an efficient model for compound development, focusing on acquiring and funding Phase 2-ready assets [2]. - The company utilizes a platform-driven approach powered by artificial intelligence (AI) and cybernetics, aiming for exits through third-party license deals after successful clinical trials [2]. - The leadership team includes experienced executives such as Dr. Andrew Regan and Dr. Freda Lewis-Hall, marking a shift from traditional pharma/biotech business models [2].

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that, following confirmation of compliance with the Bid Price and Equity Requirements as detailed in the announcement dated May 21, 2025, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s ...